A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford University, The National Institutes of Health, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Ludwig-Maximilians-Universität München, Whitehead Institute for Biomedical Research, University of Virginia School of Medicine and David Sabatini!
Full article on nature.com
